Medicinal Chemist (Protein Homeostasis)

Senior Principal Scientist, 5/22 -5/23Principal Scientist, 10/19 - 5/22Senior Research Scientist I, 11/08 – 9/19Research Scientist II, 8/05 – 10/08Medicinal Chemist conducting research to identify novel small molecule cardiovascular therapeutics with good oral bioavailability and acceptable anti-thrombotic potency with an exceptional safety profile. Contributions have led to analogues with improved selectivity over relevant enzyme panel, reduced molecular weight, improved PAMPA, increased enzymatic inhibitory affinity, increased APTT potency, and efficacy in in vivo models. Research contributions have resulted in more than 50 patents/applications and peer-reviewed journal publications

Scientist III, 1/05 – 7/05Scientist II, 6/02 – 12/04Scientist I, 3/01 – 6/02Disease Area: OncologyEGFR Tyrosine Kinase Inhibitor ProjectResearch efforts have lead to the identification and optimization of a novel, orally bioavailable class of tyrosine kinase inhibitors which has demonstrated significant in vivo antitumor activity, good PK profile, and excellent tolerability. Furthermore, contributions resulted in the evaluation of a potential pre-clinical candidate. Studies have resulted in four peer-reviewed papers.• Successfully managed project from lead discovery through advanced pre-clinical studies• Project resulted in achievement of critical milestones in newly formed small molecule drug discovery department• Improved cell-based phosphorylation potency from double-digit micromolar range to < 100 nM.• Established and maintain an excellent relationship with molecular biology and experimental therapeutics groups.• Responsible for managing and expanding the scope of intellectual property position around key structural classes• Developed better yielding, cost-effective methods of preparing multi-gram quantities of lead compounds for in vivo studies.• ImClone Systems Extraordinary Effort Award: Medicinal Chemistry Dept. Recipient (2003) RELATED RESEARCH EXPERIENCE:c-Met Tyrosine Kinase Inhibitor Project• Managed “hit-to-lead” efforts by developing and implementing initial SAR strategy for “hits” arising from high throughput screen.Tubulin Inhibitor Project (Anti-Mitotic and Vascular Disrupting Agent Strategies)• Designed and synthesized a new generation of potent small molecule tubulin inhibitors with emphasis of improving safety/tolerability, solubility, oral bioavailability and plasma half life.

Associate Scientist, 12/00 – 3/01Research Associate III, 3/98 - 12/00 Research Associate II, 5/96 - 3/98Disease Areas: Central Nervous System, Metabolic Disorders, and Oncology• Projects included the pursuit of small molecule agonist/antagonist of GPCRs and inhibitors of tyrosine protein kinases and serine/threonine protein kinases. • Performed SAR studies based on biological data and molecular modeling. • Developed solid phase and solution phase parallel synthesis of novel heterocycles and macrocycles.• Participated in SAR studies that lead to the advancement of Amgen’s first internally developed small molecule to undergo clinical evaluation. AMG706 is a selective inhibitor of kinases involved blood vessel formation and evaluated for treatment of imatinib-resistant gastrointestinal stromal tumors (Phase III).